Results 91 to 100 of about 790,096 (261)

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu, David A. Alvarez Rodriguez, Noah Gould, Alexander R. Ivanov, Kevin Jooß, Liangliang Sun   +5 more
wiley   +1 more source

Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review

Frontiers in Public Health
IntroductionWhile biosimilar medicines can contribute to the sustainability of healthcare systems, their utilization rate varies across European countries.
Sara Machado, Agostinho Cruz, Pedro Lopes Ferreira, Pedro Lopes Ferreira, Carminda Morais, Carminda Morais, Rui Esteves Pimenta, Rui Esteves Pimenta   +7 more
doaj   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Dealing with Rising Health Care Costs: The Case of Pharmaceuticals [PDF]

Pharmaceuticals; Advertising; Generic Market Entry; Reference Pricing; Parallel ...
Königbauer, Ingrid
core  

Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis

Systematic Reviews
Background Biosimilar etanercept presents itself as an innovative therapeutic opportunity for inflammatory and autoimmune diseases, however, its efficacy, safety, and immunogenicity in relation to the reference biological agent for the treatment of ...
Aurélio Matos Andrade, Juliana da Motta Girardi, Erica Tatiane da Silva, Jakeline Ribeiro Barbosa, Daniella Cristina Rodrigues Pereira   +4 more
doaj   +1 more source

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

BMC Cancer, 2018
Background The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT).
Henri Roché, Jean-Christophe Eymard, Abderraouf Radji, Alain Prevost, Rafik Diab, Michele Lamuraglia, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Alain Toledano   +8 more
doaj   +1 more source

A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.

Biologicals (Print), 2017
BACKGROUND Recombinant human granulocyte-colony stimulating factor (G-CSF, filgrastim) is used primarily to reduce incidence and duration of severe neutropenia and its associated complications in cancer patients that have received a chemotherapy regimen.
S. Brokx, Louise Scrocchi, N. Shah, Jason Dowd   +3 more
semanticscholar   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Acknowledgement to Reviewers of Pharmaceuticals in 2014

, 2015
The editors of Pharmaceuticals would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2014:[...
Pharmaceuticals Editorial Office
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source